ESOM新闻 //www.ultimamakeup.com/ ESOM最新消息 en-GB smo.org (Andrea Norsa) 弗里2024年1月12日 弗里2024年1月12日 eZ构件进化dev(http://ez构件s.org/docs/tuments/Feed) http://www.rssboard.org/rss-specification EMA推荐授权通用Eribulin //www.ultimamakeup.com/esmo/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-generic-eribulin

malyq泛泛Halaven自2011年以来一直获欧盟授权

 unreply@esmo.org be414effc9b8fae84e14efb5cbcde204 弗里2024年1月12日 上午9:00+0100 NeoadjuvantAtesolizumab加化疗安全并有前途活动 //www.ultimamakeup.com/esmo/oncology-news/neoadjuvant-atezolizumab-plus-chemotherapy-is-safe-and-has-promising-activity-in-patients-with-gastric-and-gastro-oesophageal-junction-adenocarcinoma

PANDA研究发现

 unreply@esmo.org 446063a96d2ba97955b2ea1b223a0d53 2024年1月11日 09:00+0100 CtDNANGS基础分析Imatinib抗生素二级KIT变异以选择高级GIST病人二线处理 //www.ultimamakeup.com/esmo/oncology-news/potential-value-of-ctdna-ngs-based-analysis-of-imatinib-resistant-secondary-kit-mutations-to-select-second-line-treatment-for-patients-with-advanced-gist

INTRIGUE研究探索分析结果

 unreply@esmo.org da1652a0932f65ad3d54fcf341d337d1 2024年1月10日Wed08:59:00+0100 Pemprolizumab添加切莫理疗 //www.ultimamakeup.com/esmo/oncology-news/adding-pembrolizumab-to-chemotherapy-with-or-without-bevacizumab-improves-overall-survival-across-subgroups-of-patients-with-persistent-recurrent-or-metastatic-cervical-cancer

分组分析KEYNOTE-826研究结果

 unreply@esmo.org d436140a5f61d5ea0edc4446f82d64da 2024年1月9日0:00+0100 林业局核准EnfortumabVedotin-ejfv //www.ultimamakeup.com/esmo/oncology-news/fda-approves-enfortumab-vedotin-ejfv-with-pembrolizumab-for-locally-advanced-or-metastatic-urothelial-cancer

有效性证据基础EV-302/KN-A39研究结果

 unreply@esmo.org 8a861926589d0fadf2f1275dc2cffef3 2024年1月8日上午9:00+0100 Mounetuzumab+PolatuzumabVedotin向递归复发或易碎性大B细胞Lymphome //www.ultimamakeup.com/esmo/oncology-news/mosunetuzumab-plus-polatuzumab-vedotin-shows-promise-for-patients-with-aggressive-relapsed-or-refractory-aggressive-large-b-cell-lymphoma

初级分析当前阶段Ib/II研究结果

 unreply@esmo.org ff44b8144566f29e3f91ecf3fdb64f43 Thu,2023年12月21日09:10:00+0100 等同NSCL可有效处理SBRT+护理标准,引向PFS增长 //www.ultimamakeup.com/esmo/oncology-news/oligoprogression-in-metastatic-nsclc-could-be-effectively-treated-with-sbrt-plus-standard-of-care-leading-to-increase-in-pfs-compared-with-standard-of-care-only

CURB研究发现

 unreply@esmo.org d4a361b3110f7003b37ef74554702f01 Thu,2023年12月21日 与Cetuximab组合Divarasib演示病人可管理安全简介和有希望活动与KRASG12C阳性CRC //www.ultimamakeup.com/esmo/oncology-news/divarasib-in-combination-with-cetuximab-demonstrates-a-manageable-safety-profile-and-promising-activity-in-patients-with-kras-g12c-positive-crc

剖析癌症患者发现 包含C臂Ib研究

 unreply@esmo.org 376a0aa23f1b50ef7cdd3fef5531b3e5 2023年12月20日wed Osimertinib显示前非处理病人有希望活动 //www.ultimamakeup.com/esmo/oncology-news/osimertinib-shows-promising-activity-in-previously-untreated-patients-with-metastatic-nsclc-harbouring-uncommon-egfr-mutations-other-than-the-exon-20-insertion

UNICORN研究发现

 unreply@esmo.org f88220bf2a737916cd3164ffaff23122 2023年12月19日9:00+0100 mirveuximabSoravtansine-gynx显示白金-Rese //www.ultimamakeup.com/esmo/oncology-news/mirvetuximab-soravtansine-gynx-shows-a-significant-benefit-over-chemotherapy-in-women-with-platinum-resistant-fra-positive-ovarian-cancer

MIRASOL研究发现

 unreply@esmo.org 41dfb6481c55e5509d0f47d1f85a586d 2023年12月18日Mon上午9:00+0100 FDA核准非计量立体敏感前列腺癌与生化复发 //www.ultimamakeup.com/esmo/oncology-news/fda-approves-enzalutamide-for-non-metastatic-castration-sensitive-prostate-cancer-with-biochemical-recurrence

效果证据基于EMBARK研究的结果

 unreply@esmo.org f95c211be31143beab970b252864692c 弗里2023年12月15日9:00+0100 药管局批准Pembromizumab与Chemo理疗 //www.ultimamakeup.com/esmo/oncology-news/fda-approves-pembrolizumab-with-chemotherapy-for-her2-negative-gastric-or-gastro-oesophageal-junction-adenocarcinoma

有效性证据基础为KEYNOTE-859研究结果

 unreply@esmo.org 89c335c1a45279c0a42b7fedf441c92c Thu,2023年12月14日 Talazoparib+Enzaluta //www.ultimamakeup.com/esmo/oncology-news/talazoparib-plus-enzalutamide-improves-rpfs-in-first-line-treatment-for-patients-with-mcrpc-harbouring-hrr-gene-alterations

TALAPRO-2研究发现

 unreply@esmo.org 9c48914bb137379ac77a290134e96f96 wed2023年12月13日 9:00+0100 Atesolizumab添加第一线Bevacizumab+Platinum系统改善患代谢性、持久性或复发子宫癌患者生存 //www.ultimamakeup.com/esmo/oncology-news/adding-atezolizumab-to-first-line-bevacizumab-plus-platinum-regimen-improves-survival-in-patients-with-metastatic-persistent-or-recurrent-cervical-cancer

ENGT-Cx10-GEICO68-C-JGOG1084-GOG-3030研究发现

 unreply@esmo.org 34ba130e5c13c2918ca281871c6bb6af 2023年12月12日9:00+0100 Imetstat显示持久传递自主和疾病调控活动 //www.ultimamakeup.com/esmo/oncology-news/imetelstat-shows-durable-transfusion-independence-and-disease-modifying-activity-in-heavily-transfused-patients-with-lower-risk-mds-who-are-not-responding-to-or-are-ineligible-for-esa

IMERGE研究发现

 unreply@esmo.org 05db13b1e1f1ffc9732ea5fa8c0dfd02 2023年12月11日Mon-9:00+0100 FDA批准Nirogacestatd //www.ultimamakeup.com/esmo/oncology-news/fda-approves-nirogacestat-for-desmoid-tumours

效果证据基础 DeFi研究的结果

 unreply@esmo.org c1cef936135f4f0b67cff59ba566e173 Thu, 072023 11: 00+0100 EMA推荐授权Trametinib处理低高级Glioma //www.ultimamakeup.com/esmo/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-trametinib-for-the-treatment-of-low-and-high-grade-glioma

接受正面意见治疗一岁或以上病人

 unreply@esmo.org 116ebe439103ab8de599286a62c6ebd4 Thu, 072023 10: 00+0100 软性组合Panitumab结果LongerPFS与Chemorforic KRASG12C变换mCRC //www.ultimamakeup.com/esmo/oncology-news/sotorasib-in-combination-with-panitumumab-results-in-longer-pfs-in-patients-with-chemorefractory-kras-g12c-mutated-mcrc

codeBreaK300研究发现

 noreply@esmo.org 7faf2f0f370e1788fe5582db9e13a385 wed2023年12月6日 Neoadjivant Toripalimab和Axitinib //www.ultimamakeup.com/esmo/oncology-news/neoadjuvant-toripalimab-combined-with-axitinib-demonstrates-a-promising-pathologic-response-rate-in-resectable-mucosal-melanoma

第二阶段研究发现

 unreply@esmo.org 48c5eec9dd1de5913047b1c48bb2d392 2023年5月9: 00+0100 首项研究证明PD1Imune检验屏蔽 //www.ultimamakeup.com/esmo/oncology-news/first-study-to-demonstrate-that-pd1-immune-checkpoint-blockade-may-yield-clinical-pathologic-regression-in-some-patients-with-high-risk-oral-precancerous-disease

二级非随机控制研究结果

 unreply@esmo.org 2b40d4bdb5a1445dd0a7291fa1432693 2023年12月4日Mon.00:00+0100